Maxim Group Maintains TuHURA Biosciences Buy Recommendation with 458.78% Upside Potential

Maxim Group maintained TuHURA Biosciences (HURA) with a Buy recommendation. The analyst price forecast suggests a 458.78% upside, with an average one-year price target of $11.54/share. The projected annual non-GAAP EPS is -0.30. There are 119 funds or institutions reporting positions in TuHURA Biosciences, with an average portfolio weight of 0.00%. Key shareholders include VTSMX, Geode Capital Management, IWM, VEXMX, and FSSNX.